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Finding angiogenic prognostic markers in advanced non-small-cell lung cancer is still an
unmet medical need. We explored a set of genetic variants in the VEGF-pathway as
potential biomarkers to predict clinical outcomes of patients with non-small-cell lung
cancer treated with chemotherapy plus bevacizumab. We prospectively analyzed the
relationship between VEGF-pathway components with both pathological and prognostic
variables in response to chemotherapy plus bevacizumab in 168 patients with non-
squamous non-small-cell lung cancer. Circulating levels of VEGF and VEGFR2 and
expression of specific endothelial surface markers and single-nucleotide polymorphisms
in VEGF-pathway genes were analyzed. The primary clinical endpoint was progression-July 2021 | Volume 11 | Article 6950381
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Frontiers in Oncology | www.frontiersin.orgfree survival. Secondary endpoints included overall survival and objective tumor response.
VEGFR-1 rs9582036 variants AA/AC were associated with increased progression-free
survival (p = 0.012 and p = 0.035, respectively), and with improved overall survival (p =
0.019) with respect to CC allele. Patients with VEGF-A rs3025039 harboring allele TT had
also reduced mortality risk (p = 0.049) compared with the CC allele. The VEGF-A
rs833061 variant was found to be related with response to treatment, with 61.1% of
patients harboring the CC allele achieving partial treatment response. High pre-treatment
circulating levels of VEGF-A were associated with shorter progression-free survival (p =
0.036). In conclusion, in this prospective study, genetic variants in VEGFR-1 and VEGF-A
and plasma levels of VEGF-A were associated with clinical benefit, progression-free
survival, or overall survival in a cohort of advanced non-squamous non-small-cell lung
cancer patients receiving chemotherapy plus antiangiogenic therapy.Keywords: liquid biopsy, biomarkers, NSCLC, angiogenesis, VEGFINTRODUCTION
Lung cancer is one of the most frequent malignancies, and presently
the leading cause of cancer-related deaths in Europe (1).
Approximately 85% of lung cancer cases are non-small-cell lung
cancer (NSCLC), and most NSCLC patients (70%) are diagnosed
with advanced-stage disease (i.e., stages IIIB/IV) at presentation (2).
A crucial aspect for solid tumor growth is vascularization, and
various tumors have been found to produce angiogenic factors
themselves or benefit from vascularization induced by
inflammatory mediators (3). The major regulator of angiogenesis
is vascular endothelial growth factor (VEGF) (4), whose
overexpression seems to play a most relevant role in malignant
phenotype of solid tumors, including NSCLC (5). Carboplatin-
based chemotherapy with bevacizumab has become a standard
therapy for eligible NSCLC patients after the results obtained in
trials (6–9) and observational studies (10–12). However, careful
consideration of the results within the study populations points to
the need of determining prognostic markers to select those patients
that might achieve greater benefit of treatment with these schemes.
Serum levels of VEGF isoforms and their receptors have been
used as prognostic markers and to monitor response to
chemotherapy or anti-angiogenic agents (5, 13). In fact, their levels
before therapy initiation correlate to prognosis in NSCLC (14–17),
but clinical biomarkers and these characteristics alone have been
insufficient to predict the course of the disease and response to
therapy (16, 17). Variants within VEGF-related genes seem to
regulate their transcription (18, 19), and several single-nucleotide
polymorphisms (SNPs) have been identified, some of them
influencing levels of VEGF isoforms or of their receptors in plasma
(18, 20–24). Genotype variants in proteins of the VEGF pathway have
been shown to impact patient outcomes, however with inconsistent
results (25–32), and SNPs are therefore still subject of study as
potential prognostic biomarkers. The possible role as biomarkers inl, and bevacizumab; IQR, Interquartile
ncogene; NSCLC, Non-small-cell lung
ression-free survival; SD, Standard
phism.
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NSCLC has also been widely studied in specific endothelial surface
proteins CD31, CD34, CD133, and CD146 (33, 34).
Kristen Rat Sarcoma viral oncogene (KRAS) is a well-known
driver of NSCLC for which no targeted therapy has been
developed yet. KRAS mutations have been classically defined as
a negative prognostic factor in terms of progression-free survival
(PFS) and overall survival (OS), but results are heterogenous and
the clinical significance remains controversial, also in patients
that receive platinum-based chemotherapy (35). However, SNPs
in KRAS have been related to relapse-free survival in NSCLC (36)
and PFS in colorectal cancer (37), and results suggest further
research in their potential as biomarkers in NSCLC.
Therefore, the main objective of this clinical study was to
increase insight in the correlation between selected molecular
biomarkers in genes coding for VEGF-A, VEGF receptors 1 and 2
(VEGF-R1 and VEGFR-2), and KRAS, circulating levels of
angiogenic mediators and expression of endothelial markers, and
the clinical response to the combined treatment of carboplatin,
paclitaxel, and bevacizumab in advanced NSCLC patients.
The authors present the following article in accordance with
the STROBE reporting checklist.MATERIALS AND METHODS
ANGIOMET (NCT01814163) was a case-only observational
exploratory, post-authorization study. The study has a
prospective and multicenter scheme in advanced NSCLC of
non-squamous histology, treated in first line with carboplatin-
paclitaxel-bevacizumab conducted between February 2011 and
February 2013. It was designed to investigate the relationship
between genotypes and circulating levels of selected angiogenic
mediators and the clinical outcomes and response to this
treatment scheme. Twenty hospitals of the public healthcare
system across Spain participated.
Patients and Treatment
The authors are accountable for all aspects of the work in
ensuring that questions related to the accuracy or integrity ofJuly 2021 | Volume 11 | Article 695038
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The trial was conducted in accordance with the Declaration of
Helsinki (as revised in 2013). The protocol was approved by the
Ethics Committee of Hospital General Universitario de Alicante
and was accepted by each participating center. All patients
provided written consent for inclusion.
Patients aged over 18 years with advanced non-resectable
NSCLC, metastatic or recurrent, and not previously treated with
chemotherapy were invited to participate if the treating specialist
considered the study therapy as the most appropriate. Those with
squamous or non-measurable tumors [according to RECIST 1.1
criteria (38)] or in whom peripheral blood samples could not be
obtained were excluded. Detailed inclusion and exclusion criteria
are provided in the Supplementary Appendix. Recruitment period
was 12 months, and the patients were followed for 24 months.
These patients received standard therapy of a combination of
carboplatin (AUC 6), paclitaxel (200 mg/m2), and bevacizumab
(15 mg/kg) every 21 days for a total of six cycles unless there was
evidence of disease progression or intolerance to treatment.
Sample Collection and RNA/Protein
Measurement
Peripheral blood samples were collected before the first
chemotherapy cycle and after three treatment cycles in tubes
containing EDTA as anticoagulant (BD Vacutainer®, USA) and
Blood RNA tubes (PAXgene®, USA). Samples were stored at 4°C
until DNA, RNA, or plasma extraction was performed.
Blood samples were sent to a reference laboratory within 24 h
of blood collection and subject to RNA or plasma extraction.
Two centrifugation steps were performed to obtain plasma
(10 min at 1,100 g at room temperature and a second
centrifugation of the supernatants for 10 min at 2,000 g at RT
to eliminate any possible cell fragments). Plasma aliquots were
immediately stored at −80°C until further analysis. Circulating
levels of VEGF-A and VEGFR-2 in plasma were assayed as
previously described (39); double sandwich ELISA (Duo Set,
R&D Systems) was used, in which the lower limit of detection for
VEGF-A was 31.2 pg/ml, and 15.6 pg/ml for VEGFR-2.
RNAwas isolated using the PreAnalytiX blood RNA kit (Qiagen,
Valencia, CA, USA) and quantified by spectrophotometry
in a NanoDrop2000c device (ThermoScientific, USA).
Retrotranscription was performed with 500 ng of RNA using the
High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, USA). Expression of CD31, CD34, CD133, and CD146
markers was determined by real-time quantitative PCR using
primers and probes designed with Taqman® technology (Gene
Expression Assays, Applied Biosystems). Expression of target
genes was normalized against endogenous expression of a
combination of two genes, GAPDH and CDKN1B, as a reference.
cDNA sample from a known cell line was used as a calibrator to
minimize inter-trial variability.
To analyze differences between baseline and post-treatment
samples, the circulating levels of VEGF-A and VEGFR-2 and the
expression of endothelial markers (CD31, CD34, CD133, and
CD146) were showed as ratios, calculated as the fraction between
baseline and post-treatment measurements. Results were
dichotomized in “high” and “low.” To evaluate the associationFrontiers in Oncology | www.frontiersin.org 3with survival times and response to treatment, Chi-square test or
Fisher’s Exact test were used as appropriate.
SNP Selection and Genotyping
Molecular analysis of 10 SNPs in the genes coding for VEGFR-1,
VEGFR-2, VEGF-A, and KRAS was performed by means of real-
time PCR. The SNPs analyzed were VEGFR-1 rs7996030,
VEGFR-1 rs9582036, VEGF-A rs3025039, VEGF-A rs833061,
VEGF-A rs2010963, VEGFR-2 rs2071559, VEGFR-2 rs1870377,
KRAS rs10842513, KRAS rs12813551, and KRAS rs10505980.
Details and rationale for their inclusion in molecular analysis are
provided in the supplementary material (Table S1).
Genomic DNA was extracted from the buffy coat fraction
(EDTA tubes) using QIAamp DNA blood Mini Kit (Qiagen,
Valencia, CA, USA). Real-time PCR reactions were carried out on
20 ng of DNA using predesigned assays (TaqMan® SNP
Genotyping Assay, Applied Biosystems) and master mix
containing DNA polymerase, dNTPs, and buffer (TaqMan®
genotyping master mix, Applied Biosystems®) in a final volume
of 5 µl. A positive and a negative control were included for each SNP
analyzed and each reaction plate. All samples were tested in
duplicate. The PCR conditions were as follows: 95°C for 1 min,
40 cycles of 95°C for 10 s, 60°C for 1 min. Genotypes were
discriminated using probes labeled with FAM and VIC
fluorophores in a single multiplex reaction. Fluorescence intensity
readings of the probes were measured by the ABI 7900 instrument,
and the genotypes were assigned using the SDS 2.4 Software (ABI).
All blood samples were centrally analyzed at the Research Institute
of Hospital General Universitario de Valencia (Valencia, Spain).
Endpoints and Variables
Correlation between angiogenic markers and PFS was the
primary clinical endpoint (defined as the time from treatment
initiation until disease progression or death, whichever occurred
first). OS (defined as the time from diagnosis until death from
any cause or last clinical follow-up) at 12 and 24 months and
response to treatment (classified using the RECIST 1.1. criteria in
complete response, partial response, stable disease, and disease
progression) were among the secondary endpoints. The absolute
and variable frequencies of the responses according to the
treatment are presented through contingency tables.
Statistical Methods
Sample size was estimated considering feasibility in the 20
participating hospitals, given the recruitment period, and set in
200 patients. Descriptive analysis was performed with all
variables, which were summarized as mean and standard
deviation (SD), median and interquartile range (IQR), or
frequency and proportion as appropriate. OS and PFS curves
were plotted according to the Kaplan–Meier method, and
differences between groups were assessed using the log-rank
test. Association of SNPs, circulating levels of angiogenic
mediators, and expression of endothelial markers with PFS and
OS was analyzed by means of univariate Cox regression models.
Multivariate Cox analysis was performed including all
statistically significant variables from the univariate analyses.
Clinical response to treatment was evaluated by the Chi-squareJuly 2021 | Volume 11 | Article 695038
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analyzed using Stata v16.1. software (College Station, TX:
StataCorp LLC). The level of significance was set to a = 0.05.RESULTS
Patient Characteristics
Of the 201 patients initially included in the study, two of them did
not start treatment (consent was withdrawn in one case, and
another experienced rapid deterioration); therefore, 199 received
the planned combination of carboplatin, paclitaxel, and
bevacizumab (CPB). Median age was 62 years (range 54–67), and
139 (70%) were male. Performance status at baseline was ECOG 0
or 1 in the majority (96.2%), and most of them were current
smokers or ex-smokers (85.3%). Themost frequent histological type
was adenocarcinoma (89.1%). Regarding tumor characteristics
(Table 1), all patients presented a median of two target lesions of
mean size 8.41 ± 5.63 cm, and 91.5% presented also non-target
lesions. One hundred and seventy-four patients presented two or
more metastases, of which pulmonary lymph nodes (65.2%) and
lung metastases (50.2%) were the most common (Table S2).Frontiers in Oncology | www.frontiersin.org 4Clinical Results
One hundred and sixty-eight patients had baseline valid blood
samples and complete data for the variables of interest and
outcomes analyzed. The median OS for these patients was 14.6
months (range 11.7–16.2) (Figure 1A), and the median PFS was
7.1 months (range 6.1–7.9) (Figure 1B). The OS was 80% at 6
months and 58% at 1 year. Regarding PFS, it was 59% at 6
months, and 18% after 1 year. One patient achieved complete
response, 86 achieved partial response (43.2% of the overall
sample and 51.2% among those that received at least three
cycles), and 20 (10.1%) progressed during initial therapy
(Figure 2). All patients were followed up until death,
abandonment, or end of study. Of the 199 treated patients, 11
(5.5%) died during initial therapy and 142 (71.3%) during the
follow-up period. Adverse events and other safety outcomes are
shown in Supplementary Appendix and Tables S3–S5.
Genetic Variants and Outcomes
Molecular analysis of genetic variants was performed in DNA
samples obtained from peripheral blood, and the frequencies
obtained are detailed in Table 2. Table 3 shows the results on the
association between SNPs in VEGFA, VEGFR1, VEGFR2, andTABLE 1 | Demographic and clinical characteristics of the study cohort.
N = 201 Mean (SD) Median (IQR) n (%)
Age at baseline 60.7 (9.16) 62 (54–67)




Sex Male 62 (30.8%)
Female 139 (69.2%)
Performance status ECOG 0 44 (24.2%)
ECOG 1 131 (72.0%)
ECOG 2 6 (3.3%)
ECOG 3 1 (0.5%)
Tobacco smoking history Never smoker 29 (14.7%)
Former smoker 89 (45.2%)
Packs/year 49.4 (30.6) 40 (30–56)
Smoker 79 (40.1%)
Packs/years 43.6 (21.1) 41 (27–51)
Patient previously treated Surgery 37 (18.4%)
Radiotherapy 42 (20.9%)
Neoadjuvant chemotherapy 5 (2.5%)
Adjuvant chemotherapy 7 (3.5%)
No. of target lesions 2.79 (1.65) 2 (1–9) 201 (100%)
Size (cm) 8.41 (5.63) 6.5 (4.6–11.4)
No. of non-target lesions 2.52 (1.28) 2 (1–6) 184 (91.5%)
Stage IIIB 5 (2.5%)
IV 196 (97.5%)
Histological type Adenocarcinoma 179 (89.1%)
Large cells 5 (2.5%)
Poorly differentiated adenocarcinoma 1 (0.5%)
Others 16 (8.0%)
TNM classification T N M
0 5 (2.5%) 33 (16.4%) 5 (2.5%)
1 21 (10.4%) 10 (5.0%) 196 (97.5%)
2 45 (22.4%) 77 (38.3%)
3 32 (15.9%) 57 (28.4%)
4 73 (36.3%)
X 25 (12.4%) 24 (11.9%)July 2021 | Volume 11 | Article 695038
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variants analyzed, only VEGF-A rs833061 was significantly
related with a clinical response to CPB (p = 0.036). Patients
with the CT genotype had a higher percentage of partial response
to treatment compared with patients with CC and TT alleles
(61.1 vs. 38.9 and 40.5% respectively).A
B
FIGURE 1 | Overall survival (A) and progression-free survival (B) of the
ANGIOMET cohort.FIGURE 2 | Rate of responses to chemotherapy with carboplatin and paclitaxel combined with bevacizumab.TABLE 2 | Genotype data and SNPs frequency.
Gene RF number Alleles Frequency n (%) (N = 168)
VEGFR-1 rs9582036 CC 17 (10.1%)
AA 74 (44.1%)
AC 77 (45.8%)
rs7996030 GG 95 (56.6%)
AA 7 (4.2%)
AG 66 (39.3%)
VEGFR-2 rs2071559 AA 46 (27.4%)
GG 41 (24.4%)
AG 81 (48.2%)
rs870377 AA 8 (4.8%)
TT 101 (60.1%)
AT 59 (35.1%)
VEGF-A rs3025039 CC 121 (72%)
TT 21 (12.5%)
CT 26 (15.5%)
rs833061 CC 44 (26.2%)
TT 41 (24.4%)
CT 83 (49.4%)
rs2010963 CC 11 (6.6%)
GG 79 (47%)
CG 78 (46.4%)
KRAS rs10842513 CC 143 (85.1%)
TT 2 (1.2%)
CT 23 (13.7%)
rs12813551 CC 16 (9.5%)
TT 66 (39.3%)
CT 86 (51.2%)
rs10505980 CC 73 (43.5%)
TT 18 (10.7%)
CT 77 (45.8%)July 2021 | Volume 11 | Article 695038
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in our cohort is shown in Table 4. The genetic variant in
VEGFR-1 rs9582036 was significantly associated to OS and
PFS and VEGF-A rs3025039 was significantly associated to OS
(Figure 3). Patients harboring the AA/AC alleles in VEGFR-1
rs9582036 had increased OS compared with those with CC allele,
with median OS of 17.4, 13.7 and 10.0 months, respectively.
Similarly, patients with the VEGF-A rs3025039 SNPs, TT and CT
presented half the risk of death than those patients with the CC
allele (HRTT: 0.45, p = 0.049; HRCT: 0.54, p = 0.068). On the other
hand, the PFS was significatively increased in patients with
VEGFR-1 rs9582036 AA/AC alleles (HRAA: 0.47, p = 0.012;
HRAC: 0.54, p = 0.035). No association was found in any of the
SNPs studied in KRAS and OS or PFS (Table 4).
Circulating Levels of VEGF-A and VEGFR-2
and Clinical Outcomes
We evaluated baseline VEGF-A and VEGFR-2 circulating levels
as possible biomarkers of clinical outcomes such as PFS, OS, or
treatment response to CPB (Table S6). By using the median of
each soluble marker as a cutoff, continuous variables were
dichotomized as “high” (values above the median) and “low”
(values equal or less than the median). Our results showed that
patients within the “high” VEGF-A group had significantlyFrontiers in Oncology | www.frontiersin.org 6shorter PFS [5.9 vs. 8.4 months, p = 0.036] than patients
within the “low” VEGF-A group. A similar trend (non-
statistically significant) was observed in OS (12.0 vs. 16.0
months, p = 0.095). Survival analysis was performed also for
VEGFR-2, and in this case, no significant association was found
between basal levels of this biomarker and PFS or OS.
When we analyzed the possible changes in circulating levels
of VEGF-A and VEGFR-2 between pre- and post-treatment
values (expressed as a ratio and using a cutoff value = 1), we
found no significant association with risk of death, progression,
or response to treatment either in the group with a ratio below 1
or in the group with a ratio above 1 (data not shown).
Expression of Endothelial Markers
and Prognosis
No correlations were found between expression levels of CD31,
CD34, CD146, or CD133 at baseline, post treatment, or when
ratios baseline/post-treatment (cutoff value = median) were
analyzed and correlated with PFS, OS, or response to
treatment in this study (Table S6 and data not shown).
Multivariate Analysis
A multivariate Cox regression model for PFS and OS was built
using clinical variables (PS-ECOG, gender, histology, smokingTABLE 3 | Association of SNPs in VEGFA, VEGFR1, VEGFR2, and KRAS genes with response to BCP therapy.
Gene SNP Alleles RESPONSE TO TREATMENT
Disease progression Stable disease Partial response Complete response p-value
VEGFR-1 rs9582036 CC 0 (0.0%) 6 (46.2%) 7 (53.9%) 0 (0.0%) 0.159
AA 9 (14.3%) 29 (46.0%) 25 (39.7%) 0 (0.0%)
AC 6 (8.7%) 21 (30.4%) 41 (59.4%) 1 (1.5%)
rs7996030 GG 9 (11.3%) 32 (40.0%) 38 (47.5%) 1 (1.3%) 0.909
AA 0 (0.0%) 1 (20.0%) 4 (80.0%) 0 (0.0%)
AG 6 (10.0%) 23 (38.3%) 31 (51.7%) 0 (0.0%)
VEGFR-2 rs2071559 AA 0 (0.0%) 1 (20.0%) 4 (80.0%) 0 (0.0%) 0.909
GG 9 (11.3%) 32 (40.0%) 38 (47.5%) 1 (1.3%)
AG 6 (10.0%) 23 (38.3%) 31 (51.7%) 0 (0.0%)
rs870377 AA 1 (16.7%) 3 (50.0%) 2 (33.3%) 0 (0.0%) 0.852
TT 8 (8.9%) 34 (37.8%) 47 (52.2%) 1 (1.1%)
AT 6 (12.2%) 19 (38.8%) 24 (49.0%) 0 (0.0%)
VEGF-A rs3025039 CC 12 (11.8%) 37 (36.3%) 52 (51.0%) 1 (1.0%) 0.937
TT 1 (5.3%) 9 (47.4%) 9 (47.4%) 0 (0.0%)
CT 2 (8.3%) 10 (41.7%) 12 (50.0%) 0 (0.0%)
rs833061 CC 3 (8.3%) 19 (52.8%) 14 (38.9%) 0 (0.0%) 0.036
TT 3 (8.1%) 19 (51.4%) 15 (40.5%) 0 (0.0%)
CT 9 (12.5%) 18 (25.0%) 44 (61.1%) 1 (1.4%)
rs2010963 CC 0 (0.0%) 5 (50.0%) 5 (50.0%) 0 (0.0%) 0.565
GG 8 (12.5%) 27 (42.2%) 28 (43.8%) 1 (1.6%)
CG 7 (9.9%) 24 (33.8%) 40 (56.3%) 0 (0.0%)
KRAS rs10842513 CC 13 (10.5%) 45 (36.3%) 65 (52.4%) 1 (0.8%) 0.328
TT 0 (0.0%) 0 (0.0%) 2 (100.0%) 0 (0.0%)
CT 2 (10.5%) 11 (57.9%) 6 (31.6%) 0 (0.0%)
rs12813551 CC 1 (6.3%) 4 (25.0%) 11 (68.8%) 0 (0.0%) 0.168
TT 4 (7.0%) 29 (50.9%) 24 (42.1%) 0 (0.0%)
CT 10 (13.9%) 23 (31.9%) 38 (52.8%) 1 (1.4%)
rs10505980 CC 5 (7.9%) 31 (49.2%) 27 (42.9%) 0 (0.0%) 0.216
TT 1 (6.3%) 4 (25.0%) 11 (68.8%) 0 (0.0%)
CT 9 (13.6%) 21 (31.8%) 35 (53.0%) 1 (1.5%)July 2021 | Volume 11 | ArticleP-values marked with bold indicate statistically significant p-values.695038
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the univariate analysis. Regarding PFS, this analysis revealed that
only the VEGFR-1 rs9582036 and baseline circulating levels of
VEGF-A were independent prognostic variables (p = 0.012 and
p = 0.042, respectively) in our patient population. Moreover,
ECOG-PS, VEGFR-1 rs9582036, and VEGF-A rs3025039 were
found as independent markers for OS (p = 0.004, p = 0.018 and
p = 0.007, respectively) in our study.DISCUSSION
There is a strong unmet need for new biomarkers that can
predict clinical responses to various therapies in patients with
NSCLC, facilitating a more individualized treatment. During the
last years, several studies have evaluated different molecules
related to VEGF pathway in relation to clinical outcomes in
patients with NSCLC treated with CPB regimen, but until now,
there are no validated predictive biomarkers in the clinical
setting (40). This prospective study contributes to the body of
evidence demonstrating the potential of some biomarkers,
including SNPs in angiogenic genes and circulating levels of
VEGF, as prognostic factors in NSCLC. Our results show that
both VEGFR-1 rs9582036 and VEGF-A rs3025039 wereFrontiers in Oncology | www.frontiersin.org 7independent prognostic markers for OS. Moreover, shorter
PFS correlates with higher baseline plasma levels of VEGF-A
and the presence of the CC allele in VEGFR-1 rs9582036. Then,
we propose the analysis of variants in VEGFR-1 and VEGF-A as
potential biomarkers in patients with NSCLC treated with CPB.
Several studies have l inked rs9582036 VEGFR-1
polymorphism and clinical outcomes in bevacizumab-treated
patients with different kinds of cancer (36, 41, 42). The CC
allele of rs9582036 variant was predictive of shorter survival in
pancreatic and colorectal cancer (41, 42). Regarding NSCLC
patients, the study performed by Glubb et al. (36) in 2015 showed
that AA variants of rs9582036 were associated with longer
relapse-free survival independent of the treatment, and were
proposed as a prognostic biomarker in stage I-III NSCLC (36).
Our results found that the CC rs9582036 allele has a negative
predictive effect in patients with advanced NSCLC treated with
chemotherapy plus bevacizumab, while the AA and AC variants
are associated with an increase in PFS and OS. Taken together,
these data suggest that carriers of the CC allele of the VEGFR-1
variant rs9582036 may be less responsive to angiogenesis
inhibition having a detrimental effect on survival. However,
one should consider that the VEGFR-1 variants found in our
study were detected in peripheral blood, while the SNPs reported
in the study by Glubb et al. (36) were found in somaticTABLE 4 | Association of SNPs in VEGFA, VEGFR1, VEGFR2, and KRAS genes with OS and PFS.
Gene RF number Alleles OS PFS
HR (CI 95%) p HR (CI 95%) p
VEGFR-1 rs9582036 CC REF – – –
AA 0.39 (0.20 - 0.78) 0.007 0.47 (0.26 - 0.85) 0.012
AC 0.54 (0.29 – 1.03) 0.060 0.54 (0.30 – 0.96) 0.035
rs7996030 GG REF – – –
AA 1.29 (0.40 - 4.18) 0.674 1.82 (0.72 - 4.58) 0.206
AG 1.25 (0.80 - 1.94) 0.328 1.31 (0.92 – 1.87) 0.134
VEGFR-2 rs2071559 AA REF – – –
GG 1.42 (0.77 - 2.63) 0.260 1.40 (0.86 - 2.27) 0.175
AG 1.23 (0.74 – 2.05) 0.423 1.16 (0.77 - 1.74) 0.473
rs870377 AA REF – – –
TT 0.70 (0.30 - 1.65) 0.418 0.77 (0.35 - 1.68) 0.512
AT 0.85 (0.35 - 2.03) 0.713 0.83 (0.38 - 1.84) 0.648
VEGF-A rs3025039 CC REF – – –
TT 0.45 (0.21 - 0.99) 0.048 (0.59 - 1.61) 0.917
CT 0.54 (0.28 – 1.05) 0.068 (0.43 – 1.16) 0.172
rs833061 CC REF – – –
TT 0.88 (0.50 - 1.56) 0.666 0.86 (0.53 - 1.40) 0.82
CT 0.65 (0.38 - 1.08) 0.097 0.82 (0.54 – 1.24) 0.354
rs2010963 CC REF – – -
GG 1.59 (0.57 - 4.45) 0.378 0.89 (0.42 - 1.87) 0.762
CG 1.52 (0.55 – 4.26) 0.421 0.77 (0.36 – 1.62) 0.484
KRAS rs10842513 CC REF – – –
TT 0.81 (0.11 - 5.87) 0.836 1.15 (0.28 - 4.69) 0.841
CT 1.26 (0.69 – 2.28) 0.455 1.39 (0.85 - 2.27) 0.192
rs12813551 CC REF – – –
TT 0.44 (0.17 - 1.14) 0.092 0.86 (0.46 - 1.60) 0.635
CT 0.91 (0.58 – 1.41) 0.662 0.95 (0.66 - 1.37) 0.773
rs10505980 CC REF – – –
TT 0.65 (0.29 - 1.47) 0.288 1.32 (0.76 - 2.31) 0.328
CT 0.86 (0.55 – 1.35) 0.517 0.93 (0.64 - 1.34) 0.693July 2021 | Volume 11 | Article 6Multiple Cox-regression allelic model for PFS and OS was performed.
P-values marked with bold indicate statistically significant p-values.95038
Jantus-Lewintre et al. Angiogenic Biomarkers After Bevacizumb Plus Chemotherapy in NSCLCtumor cells. Considering all these pieces of evidence supporting
the role of the rs9582036 polymorphism in VEGFR-1 in
treatment response and outcome in NSCLC, more studies are
needed to understand the molecular mechanism of VEGFR-1
genetic variation in response to VEGF blockage.
Additionally, we found that patients harboring both the TT
and CT alleles in rs3025039 VEGF-A had reduced their risk of
death by approximately half compared to CC. Again, there is
some controversy in the literature regarding the effect of this SNP
in lung cancer clinical outcomes. While patients with advance
NSCLC treated with chemoradiotherapy showed no significant
association with survival (43), a trend toward improved survival
was observed in early-stage NSCLC patients treated with surgical
resection, in concordance with our findings (30). In line with
these results, Chen et al. reported that patients with the TT allele
treated with chemotherapy presented lower risk of death from all
causes (44).
Only VEGF-A rs833061 polymorphism was found to be
significantly associated with response to treatment in our
study. Previous reports have already demonstrated a potential
role of this particular SNP in the metastatic capacity of many
tumors, including NSCLC (26, 30, 45–47). Regarding its impact
on the therapeutic efficiency of bevacizumab plus chemotherapy,
our analysis showed that more than 60% of the rs833061 CT
carriers had a clinical benefit of the treatment. That agrees with
the exploratory study performed by Pallaud et al. in 2014 (27),Frontiers in Oncology | www.frontiersin.org 8showing increased best overall response to first-line bevacizumab
plus chemotherapy treatment in patients harboring this allele.
These data provide strong evidence of the predictive value of
rs833061 SNP as potential biomarker for response to anti-
VEGF therapy.
We also investigated whether expression profiles of
circulating VEGF-A and VEGFR-2 could be of clinical interest
for finding predictors of clinical outcomes to CPB in NSCLC. We
found that high pre-treatment VEGF-A plasma levels were
associated with less favorable prognosis, increasing the risk of
progression. In recent years, some studies have also explored the
usefulness of measuring the levels of angiogenic factors as
prognostic or predictive markers in NSCLC (25–28, 30, 31, 36,
48). Sanmartıń et al. identified a signature of angiogenic factors
related with NSCLC outcome (48). Particularly, patients with
high levels of VEGF-A and low expression of VEGF-B and
VEGF-D had worse OS and lower relapse-free survival. A
metanalysis including 74 studies and 7,631 patients found that
VEGF-A overexpression was an independent prognostic factor in
early-stage NSCLC (49). Regarding the role of circulating levels
of VEGF-A, there are evidences showing an association between
higher levels of this angiogenic mediator and worse clinical
outcomes in NSCLC (49, 50). All together, these results suggest
that high levels of VEGF-A could be associated with negative
outcomes in NSCLC. Since VEGF-A is a target of bevacizumab
treatment, one possible explanation of the effects of higherA B
C
FIGURE 3 | Effect of the polymorphism in VEGFR-1 rs9582036 in estimated OS (A) and PFS (B), and in VEGFA rs3025039 in estimated OS (C).July 2021 | Volume 11 | Article 695038
Jantus-Lewintre et al. Angiogenic Biomarkers After Bevacizumb Plus Chemotherapy in NSCLCconcentrations of VEGF-A in peripheral blood is directly related
to a lower therapeutic effect of this drug. Evaluation of VEGF
levels in lung cancer development and in response to therapy
might suppose an important tool to better understand its
prognostic impact.
The limitations of this study include its exploratory nature,
since the sample size followed the feasibility criteria and is
limited. Also, the SNP panel used is limited, and it should be
extended in order to test other SNPs, specifically in VEGF-A, that
have shown an association with clinical outcomes in other
cancers. On the other hand, this is one of the few studies that
prospectively evaluated the effect of different angiogenesis
biomarkers in liquid biopsies in the NSCLC setting, accurately
collecting information and eliminating any recall bias.
The results of this prospective study support previous
findings regarding the influence of SNPs on angiogenic VEGF
genes, and the circulating levels of VEGF on the clinical
outcomes of patients with non-squamous NSCLC receiving
antiangiogenic treatment such as bevacizumab. In most cases,
consistent results across studies are lacking, warranting further
research on the subject before molecular biomarkers can be
useful in selecting patients with NSCLC and being included in
treatment algorithms for antiangiogenic agents. However,
important advances are being made in other cancer types,
including breast cancer, in which a recent study has found an
association of independent prognostic factors with specific
treatments and has weighted them by the outcome category (51).DATA AVAILABILITY STATEMENT
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Carrioń, Artal, Rolfo, de Castro, Guillot, Oramas, de las Peñas, Ferrera, Martıńez,
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